This inventor holds 23 USPTO granted patents and 24 published patent applications, plus 1 CIPO patent, primarily in Kappa Agonist Compounds. Top assignees: Adolor Corporation, Apolor Corp.. Active years: 1997-2007.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1997-2007
Areas of Expertise:
Title: Innovator Spotlight: Wei Yuan Zhang
Introduction: Wei Yuan Zhang, based in Collegeville, PA, is a prolific inventor known for his significant contributions to the field of pharmaceutical sciences. With a remarkable portfolio of 23 patents, Zhang has focused his research on kappa agonist compounds and their applications in treating various medical conditions.
Latest Patents: Among Zhang's latest innovations are patents for kappa agonist compounds and their pharmaceutical formulations. These compounds exhibit kappa opioid agonist activity and are designed for use as analgesics and pruritic agents. Notable patents include methodologies addressing both the prevention and treatment of pruritus through the administration of effective amounts of kappa opioid receptor agonist compounds, represented by specific chemical formulae. These advancements mark significant strides in pharmaceutical research aimed at enhancing patient care and treatment efficacy.
Career Highlights: Throughout his career, Wei Yuan Zhang has made impactful contributions while working with notable companies, including Adolor Corporation and Apolor Corp. His dedication to innovation and research has positioned him as a leader in developing therapeutic solutions that address unmet medical needs.
Collaborations: Collaborating with esteemed colleagues such as Virendra Kumar and An-Chih Chang has further enriched Zhang's research endeavors. These partnerships have fostered a collaborative environment conducive to groundbreaking discoveries in the pharmaceutical field.
Conclusion: Wei Yuan Zhang's innovative spirit and dedication to his research continue to influence the landscape of pharmaceutical sciences. With a robust patent portfolio, his work on kappa agonist compounds illustrates a commitment to advancing medical treatment options and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile